18Feb 2017

GLYCATED HEMOGLOBIN (HBA1C) IS A PREDICTOR OF DYSLIPIDEMIA IN TYPE 2 DIABETES NEPALESE PATIENTS.

  • Department of Laboratory Medicine, Manmohan Memorial Institute of Health Sciences, Kathmandu, Nepal.
  • Department of Biochemistry, College of Medicine, Nepalese Army Institute of Health Sciences, Kathmandu, Nepal.
  • Department of Microbiology, Faculty of Medicine, Khon Kaen University, Thailand.
  • College of Applied Medical Sciences, Al Jouf University, Al Qurayyat, Saudi Arabia.
  • Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Type 2 diabetes mellitus (T2DM) have an increased prevalence of dyslipidemia. Dyslipidemia is characterized by high cholesterol (TC), high triglyceride (TG), high LDL cholesterol (LDL-C) and decrease HDL cholesterol (HDL-C) and is major risk factor for cardiovascular disease in T2DM. HbA1c serve as a gold standard indicator of glycaemic status over long term. Aim: The study aimed to investigate the correlations between lipid profile parameters, as well as the glycated hemoglobin (HbA1c) values of Nepalese population with type 2 Diabetes mellitus (T2DM). Material and Methods: This was a cross sectional, retrospective study of 140 T2DM patients (81 male and 59 female) who had visited department of Internal Medicine, Manmohan Memorial Community Hospital were included in this study. Venous blood samples were collected for fasting plasma glucose, HbA1c and serum lipid profile from all subjects in the morning after at least 8 hours fasting by using methods following standard operating procedures (SOPs). The statistical analysis was done by SPSS. Results: There is alteration in the serum levels of FBS, total cholesterol (TC), triglycerides, LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) were noted in patients with T2DM. The HbA1c was found to be significant correlation with FBS, TC, TG, and LDL-C but there was no significant relation noticed with HDL-C. Values of HbA1c >6.5 % showed significant correlation with TC, LDL-C, TG, LDL-C/HDL-C and TC/HDL-C ratio, as compared to patients with HbA1c ? 6.5% (p<0.05). Conclusion: In conclusion, our study demonstrates that in Nepalese with type 2 diabetes mellitus, dyslipidemia is more common. To reduce the burden of morbidity and mortality from different complications, it necessary to control diabetes and lipid levels in diabetic patients and emphasises the additional possible use of HbA1c as a predictor for dyslipidemia.

  1. Sulaiman Amur Al-Alawi. Serum lipid profile and glycated hemoglobin status in Omani patients with type2 diabetes mellitus attending a primary care polyclinic. Biomedical Research 2014; 25 (2): 161-6.
  2. Pujari SS. Hba1c as Marker of Dyslipedemia in Type 2 Diabetes Mellitus Patients. Sch. J. App. Med. Sci., 2013; 1(6):728-31.
  3. Sreenivas Reddy A, Meera S, Ebenezer W, Kumar JS. Correlation between glycemic control and lipid profile in type 2 diabetic patients: HbA1c as an indirect indicator of dyslipidemia. Asian J Pharm Clin Res, 2014; 7(2):153-5.
  4. Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond) 2005;2:29.
  5. Mooradian AD, Haas MJ, Wehmeier KR, Wong NC. Obesity related changes in high density lipoprotein metabolism. Obesity (Silver Spring). 2008; 16: 1152-60.
  6. Mooradian AD, Haas MJ, Wong NC. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes. 2004; 53: 513-20.
  7. Vinod Mahato R , Gyawali P, Raut P, Regmi P, Singh K, Pandeya DR. Association between glycaemic control and serum lipid profile in type 2diabetic patients: glycated haemoglobin as a dual biomarker. Biomed Res 2011; 22: 375-80.
  8. Al-Lawati JA, N Barakat M, Al-Zakwani I, Elsayed MK, Al-Maskari M, M Al-Lawati N, Mohammed AJ. Control of risk factors for cardiovascular disease among adults with previously diagnosed type 2 diabetes mellitus: a descriptive study from a middle eastern arab population. Open Cardiovasc Med J.2012;6:133-40.
  9. American Diabetes Association. Dyslipidemia management in adult with diabetes. Diabetes Care 2004;24: s68-s71.
  10. Chintamani Bodhe, Deepali Jankar, Tara Bhutada, Milind Patwardhan, and Varsha Patwardhan. HbA1c: Predictor of Dyslipidemia and Atherogenicity in Diabetes Mellitus. IJBMSP. 2012;2(1):25-7.
  1. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 2010;268: 471-82.
  2. Oh HG, Rhee EJ, Kim TW, Lee KB, Park JH, Yang KI, Jeong D, Park HK.. Higher glycated hemoglobin level is associated with increased risk for ischemic stroke in non-diabetes korean male adults. Diabetes Metab J 2011;35: 551-7.
  3. Joslin’s Diabetes Mellitus 14th Ed Lippincott Williams & Wilkins Chapter 33: Genearl approach to the treatment of diabetes mellitus.
  4. Gotto AM Jr; Cardiologist’s role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus. Am J Cardiol. 2007; 99 (4A): 3B–5B.
  5. Bantle JP, Wylie Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, et al. Nutrition recommendations and interventions for diabetes 2006: a position statement of the American Diabetes Association. Diabetes Care. 2006; 29: 2140-57.
  6. Steiner G. Fibrates. Statins versus Fibrates in the Treatment of Diabetic Dyslipidemia.    Program     and abstracts of the 61st Scientific Sessions of the American Diabetes Association. 2001.
  7. Arshag D Mooradian. Nat Clin Pract Endocrinol Metabol 2009; 5(3):150-9.
  8. Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lipids in Health and Disease 2014; 13:183.
  9. Walden C, Knopp R, Wahl P et al (1984) Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 311:953-9.
  10. Sulaiman Amur Al-Alawi. Serum lipid profile and glycated hemoglobin status in Omani patients with type2 diabetes mellitus attending a primary care polyclinic. Biomedical Research 2014; 25 (2): 161-6.
  11. Mohamad M, Arshad F, Noor MIM, Ali R (1997) Prevalence of dyslipidemia in non-insulin-dependent diabetic patients attending armed forces clinics in Kuala Lumpur. Asia Pacific J Clin Nutr 6:203–206
  12. Esteghamati A, Abbasi M, Nakhjavani M et al. Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. Cardiovasc Diabetol. 2006;5:15.
  13. Khaw K.T., Wareham N., Bingham S., Luben R., Welch A. and Day N. (2004) Association of haemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med; 141: 413-20.
  14. Chan WB, Tong PC, Chow CC. Triglyceride predicts cardiovascular mortality and its relationship with glycemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev 2005; 21: 183-8.
  15. Faulkner MS, Chao WH, Kamth SK. Total homocysteine, diet and lipid profiles in type 1 and type 2 diabetic and non-diabetic adolescents. J Cardiovasc Nurs 2006; 21: 47-55.
  16. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC et al.; Glycated hemoglobin and cardiovascular risk fac-tors in Chinese subjects with normal glucose tolerance. Diabet Med.,1998; 15(7): 573-8.
  17. Hammed IK, Abed BA, Rashid NF. Glycated haemoglobin as a dual biomarker association between HbA1c and dyslipidemia in type 2 diabetic patients. J Fac Med Baghdad. 2012; 54: 88-92.
  18. Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 2007;7:24-9.

[Pooja Maharjan, Dipendra Raj Pandeya, Govardhan Joshi, Sakrita Hona, Bibek Bhatta, Alneil M. Hamza and Mohammed H. Saiem Al Dahr. (2017); GLYCATED HEMOGLOBIN (HBA1C) IS A PREDICTOR OF DYSLIPIDEMIA IN TYPE 2 DIABETES NEPALESE PATIENTS. Int. J. of Adv. Res. 5 (Feb). 113-121] (ISSN 2320-5407). www.journalijar.com

Dr. Dipendra Raj Pandeya
1.College of Applied Medical Sciences, Al Jouf University, Al Qurayyat Saudi Arabia. 2.Department of Biochemistry, College of Medicine, Nepalese Army Institute of Health Sciences, Kathmandu, Nepal

DOI:

Article DOI: 10.21474/IJAR01/3121      
DOI URL: http://dx.doi.org/10.21474/IJAR01/3121

Download Full Paper

Download PDF No. of Downloads: 113 | No. of Views: 340